Global Inhaled Nitric Oxide Market

Inhaled Nitric Oxide Market Size, Share, Growth Analysis, By Product type(Gas and Delivery System), By Application(Neonatal Respiratory Treatment, Asthma & COPD, Acute Respiratory Distress Syndrome and Malaria Treatment), By End User(Near-term & Pre-term Infants PPHN, Children & Adult ARDS, and Other Diseases), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2329 | Region: Global | Published Date: April, 2024
Pages: 218 | Tables: 88 | Figures: 75

Inhaled Nitric Oxide Market News

  • In February 2023, Vero Biotech announced that Genosyl, a second-generation anesthetic, has been approved by the FDA for use in functional rooms. Second-generation Genosyl was produced by Vero Biotech specifically for the administration of inhaled nitric oxide. The FDA just approved a third-generation gadget; however, it hasn't been tested using rebreathing anesthesia yet.
  • In May 2023, the safety survey of the 10 mg dry powder amount safety cohort from the most recent multi-center placebo-organized phase 2a study was announced by Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company that advances new biotherapeutics throughout its proprietary Anticalin technology stage for a respiratory disorder and cancer.
  • In August 2022, A two-year USD 600,000 Small Business Innovation Research (SBIR) grant was given to Zylo Therapeutics Inc. to help develop the company's unique topical medication that releases nitric oxide for the treatment of onychomycosis. The National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health (NIH), is the sponsor of the funding.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Inhaled Nitric Oxide market size was valued at USD 951.72 million in 2022 and is poised to grow from USD 1027 million in 2023 to USD 1755 million by 2031, at a CAGR of 7.95% in the forecast period (2024-2031).

Several significant worldwide firms vying for market supremacy define the competitive landscape of the inhaled nitric oxide market. To improve their position in the industry, major firms like Novoteris, Linde plc, Praxair Inc., Mallinckrodt Pharmaceuticals, and Air Liquide are actively working on new products, forming strategic alliances, and merging. To take advantage of the rising demand for inhaled nitric oxide therapy globally, these companies are concentrating on broadening their product offerings and geographic reach. 'Perma Pure LLC (US)', 'Merck KGaA (Germany)', 'Zylo Therapeutics Inc. (US)', 'HALMA PLC (UK)', 'Pieris Pharmaceuticals (US)', 'Air Liquide Healthcare (France)', 'Bellerophan Therapeutics Inc. (US)', 'Mallinckrodt Pharmaceuticals (Novoteris) (US)', 'Matheson Tri-Gas Inc. (US)', 'BOC Healthcare (UK)', 'Vero Biotech (US)', 'Nu-Med Plus Inc. (US)', 'Praxair Distribution Inc. (US)', 'LINDE PLC (UK)', 'Beyond Air', 'Taiyo Nippon Sanso Corporation', 'Praxair, Inc. (now part of Linde plc)', 'Novoteris, LLC', 'Nu-Med Plus, Inc.'

The market for inhaled nitric oxide is significantly driven by the rising prevalence of respiratory illnesses. The need for inhaled nitric oxide as a therapy option is anticipated to increase if these disorders continue to impact many people globally. Exposure to air pollution, cigarette smoke, and occupational risks are examples of environmental contaminants that can have a substantial impact on respiratory health and raise the chance of acquiring respiratory disorders. The ageing population's weakening immune systems and inherent changes in lung function make them more vulnerable to respiratory diseases. It is anticipated that the prevalence of respiratory illnesses would increase as the world's population ages.

Growing Impact of Asthma and COPD: Among the most prevalent respiratory illnesses impacting the public are asthma and COPD, both of which can be fatal and impair a patient's daily ability to breathe. Chronic asthma is a disorder that causes the lungs' air passageways to expand and constrict, which results in attacks of dyspnea, bronchospasm, and reversible airflow blockage. A significant increase in cigarette usage exacerbates the symptoms of COPD and asthma. Furthermore, because of increased industrialization, there are now more occurrences of COPD and asthma, which could drive up demand for inhaled nitric oxide during the projection period.

Throughout the anticipated period, North America is anticipated to maintain its prominent position in the inhaled nitric oxide market. This is since there are recognized organizations for research and development as well as a modern healthcare infrastructure. To deliver inhaled nitric oxide therapy, North America offers sophisticated healthcare facilities, including clinics and hospitals, as well as the knowledge and resources to do so. During the anticipated period, the inhaled nitric oxide market is expected to grow at the quickest rate in Europe. This is due to the presence of significant regional players, continuing research, and clinical trials regarding the safety and effectiveness of inhaled nitric oxide. In Europe, pulmonary hypertension is a prevalent ailment that impacts many people.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Nitrous Oxide Market
Buy Now GET FREE SAMPLE
Nitric Acid Market
Buy Now GET FREE SAMPLE
Therapeutic Respiratory Devices Market
Buy Now GET FREE SAMPLE
Sodium Nitrite Market
Buy Now GET FREE SAMPLE
COPD and Asthma Devices Market
Buy Now GET FREE SAMPLE
Respiratory Devices Market
Buy Now GET FREE SAMPLE
Respiratory Disease Testing Market
Buy Now GET FREE SAMPLE
Smart Inhalers Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Inhaled Nitric Oxide Market

Report ID: SQMIG35I2329

$5,300
BUY NOW GET FREE SAMPLE